Quarterly report · Q2
7745.TEDINET S100PKQD
Period2022-04-01 → 2022-09-30
Filed2022-11-11
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 49
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥27.2bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Revenue | ¥51.7bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥23.9bn | 2021-04-01 → 2021-09-30 | Cons. | Net sales |
| Operating income | ¥1.8bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Operating income | ¥2.1bn | 2021-04-01 → 2021-09-30 | Cons. | Operating income |
| Ordinary income | ¥2.2bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥5.6bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.2bn | 2021-04-01 → 2021-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥2.2bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥2.2bn | 2021-04-01 → 2021-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.5bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥3.6bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.4bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥1.5bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Net income | ¥1.5bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss |
| Total assets | ¥66.3bn | at 2022-09-30 | Cons. | Assets |
| Total assets | ¥59.2bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥54.5bn | at 2021-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥34.3bn | at 2022-09-30 | Cons. | Liabilities |
| Total liabilities | ¥32.2bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥32.0bn | at 2022-09-30 | Cons. | Net assets |
| Net assets / equity | ¥27.0bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥24.4bn | at 2021-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥13.5bn | at 2022-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥11.9bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥12.8bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥11.0bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥11.1bn | at 2021-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥12.1bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥1.4bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.8bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥2.2bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥626m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥2.4bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.4bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥317m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥741m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.9bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥53.43 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥59.25 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥172.92 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥66.02 | 2021-04-01 → 2021-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥38.37 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥53.38 | 2022-04-01 → 2022-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥172.66 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥65.91 | 2021-04-01 → 2021-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 48.1% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 40.8% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 40.0% | at 2021-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 97
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥13.9bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥13.9bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥1.8bn |
| jpcrp040300-q2r_E02344-000America Measuring Instrumentsreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥3.3bn |
| jpcrp040300-q2r_E02344-000America Measuring Instrumentsreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥3.1bn |
| jpcrp040300-q2r_E02344-000America Measuring Instrumentsreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥211m |
| jpcrp040300-q2r_E02344-000America Measuring Instrumentsreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥370m |
| jpcrp040300-q2r_E02344-000America Medical And Health Systemreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥4.3bn |
| jpcrp040300-q2r_E02344-000America Medical And Health Systemreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥4.3bn |
| jpcrp040300-q2r_E02344-000America Medical And Health Systemreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥0 |
| jpcrp040300-q2r_E02344-000America Medical And Health Systemreportable segment | segment profit | 2022-04-01 → 2022-09-30 | −¥29m |
| jpcrp040300-q2r_E02344-000Asia And Oceania Measuring Instrumentsreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥4.2bn |
| jpcrp040300-q2r_E02344-000Asia And Oceania Measuring Instrumentsreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥2.6bn |
| jpcrp040300-q2r_E02344-000Asia And Oceania Measuring Instrumentsreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥1.7bn |
| jpcrp040300-q2r_E02344-000Asia And Oceania Measuring Instrumentsreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥317m |
| jpcrp040300-q2r_E02344-000Asia And Oceania Medical And Health Systemreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥4.9bn |
| jpcrp040300-q2r_E02344-000Asia And Oceania Medical And Health Systemreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥245m |
| jpcrp040300-q2r_E02344-000Asia And Oceania Medical And Health Systemreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥4.7bn |
| jpcrp040300-q2r_E02344-000Asia And Oceania Medical And Health Systemreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥252m |
| jpcrp040300-q2r_E02344-000Europe Measuring Instrumentsreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥471m |
| jpcrp040300-q2r_E02344-000Europe Measuring Instrumentsreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥470m |
| jpcrp040300-q2r_E02344-000Europe Measuring Instrumentsreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥0 |
| jpcrp040300-q2r_E02344-000Europe Measuring Instrumentsreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥52m |
| jpcrp040300-q2r_E02344-000Europe Medical And Health Systemreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥4.0bn |
| jpcrp040300-q2r_E02344-000Europe Medical And Health Systemreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥4.0bn |
| jpcrp040300-q2r_E02344-000Europe Medical And Health Systemreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥0 |
| jpcrp040300-q2r_E02344-000Europe Medical And Health Systemreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥527m |
| jpcrp040300-q2r_E02344-000Japan Measuring Instrumentsreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥9.0bn |
| jpcrp040300-q2r_E02344-000Japan Measuring Instrumentsreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥7.0bn |
| jpcrp040300-q2r_E02344-000Japan Measuring Instrumentsreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥1.9bn |
| jpcrp040300-q2r_E02344-000Japan Measuring Instrumentsreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥76m |
| jpcrp040300-q2r_E02344-000Japan Medical And Health Systemreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥8.2bn |
| jpcrp040300-q2r_E02344-000Japan Medical And Health Systemreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥2.8bn |
| jpcrp040300-q2r_E02344-000Japan Medical And Health Systemreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥5.5bn |
| jpcrp040300-q2r_E02344-000Japan Medical And Health Systemreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥1.2bn |
| jpcrp040300-q2r_E02344-000Japan Semiconductor Relatedreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥2.6bn |
| jpcrp040300-q2r_E02344-000Japan Semiconductor Relatedreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥2.6bn |
| jpcrp040300-q2r_E02344-000Japan Semiconductor Relatedreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥845m |
| jpcrp040300-q2r_E02344-000Measuring Instrumentsreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥17.0bn |
| jpcrp040300-q2r_E02344-000Measuring Instrumentsreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥13.2bn |
| jpcrp040300-q2r_E02344-000Measuring Instrumentsreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥3.8bn |
| jpcrp040300-q2r_E02344-000Measuring Instrumentsreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥817m |
| jpcrp040300-q2r_E02344-000Medical And Health Systemreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥21.5bn |
| jpcrp040300-q2r_E02344-000Medical And Health Systemreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥11.4bn |
| jpcrp040300-q2r_E02344-000Medical And Health Systemreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥10.1bn |
| jpcrp040300-q2r_E02344-000Medical And Health Systemreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥2.0bn |
| jpcrp040300-q2r_E02344-000Semiconductor Related Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥2.6bn |
| jpcrp040300-q2r_E02344-000Semiconductor Related Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥2.6bn |
| jpcrp040300-q2r_E02344-000Semiconductor Related Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥845m |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-09-30 | −¥11.4bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-09-30 | −¥11.4bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-09-30 | −¥979m |
| jpcrp040300-q2r_E02344-000America Measuring Instrumentsreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥1.8bn |
| jpcrp040300-q2r_E02344-000America Measuring Instrumentsreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥1.7bn |
| jpcrp040300-q2r_E02344-000America Measuring Instrumentsreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥115m |
| jpcrp040300-q2r_E02344-000America Measuring Instrumentsreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥68m |
| jpcrp040300-q2r_E02344-000America Medical And Health Systemreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥3.5bn |
| jpcrp040300-q2r_E02344-000America Medical And Health Systemreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥3.5bn |
| jpcrp040300-q2r_E02344-000America Medical And Health Systemreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥3m |
| jpcrp040300-q2r_E02344-000America Medical And Health Systemreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥120m |
| jpcrp040300-q2r_E02344-000Asia And Oceania Measuring Instrumentsreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥3.4bn |
| jpcrp040300-q2r_E02344-000Asia And Oceania Measuring Instrumentsreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥2.1bn |
| jpcrp040300-q2r_E02344-000Asia And Oceania Measuring Instrumentsreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥1.3bn |
| jpcrp040300-q2r_E02344-000Asia And Oceania Measuring Instrumentsreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥229m |
| jpcrp040300-q2r_E02344-000Asia And Oceania Medical And Health Systemreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥3.9bn |
| jpcrp040300-q2r_E02344-000Asia And Oceania Medical And Health Systemreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥274m |
| jpcrp040300-q2r_E02344-000Asia And Oceania Medical And Health Systemreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥3.6bn |
| jpcrp040300-q2r_E02344-000Asia And Oceania Medical And Health Systemreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥114m |
| jpcrp040300-q2r_E02344-000Europe Measuring Instrumentsreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥437m |
| jpcrp040300-q2r_E02344-000Europe Measuring Instrumentsreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥437m |
| jpcrp040300-q2r_E02344-000Europe Measuring Instrumentsreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥7m |
| jpcrp040300-q2r_E02344-000Europe Medical And Health Systemreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥3.7bn |
| jpcrp040300-q2r_E02344-000Europe Medical And Health Systemreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥3.7bn |
| jpcrp040300-q2r_E02344-000Europe Medical And Health Systemreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥4m |
| jpcrp040300-q2r_E02344-000Europe Medical And Health Systemreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥473m |
| jpcrp040300-q2r_E02344-000Japan Measuring Instrumentsreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥9.0bn |
| jpcrp040300-q2r_E02344-000Japan Measuring Instrumentsreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥7.4bn |
| jpcrp040300-q2r_E02344-000Japan Measuring Instrumentsreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥1.5bn |
| jpcrp040300-q2r_E02344-000Japan Measuring Instrumentsreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥155m |
| jpcrp040300-q2r_E02344-000Japan Medical And Health Systemreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥7.5bn |
| jpcrp040300-q2r_E02344-000Japan Medical And Health Systemreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥2.7bn |
| jpcrp040300-q2r_E02344-000Japan Medical And Health Systemreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥4.8bn |
| jpcrp040300-q2r_E02344-000Japan Medical And Health Systemreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥1.3bn |
| jpcrp040300-q2r_E02344-000Japan Semiconductor Relatedreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥2.1bn |
| jpcrp040300-q2r_E02344-000Japan Semiconductor Relatedreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥2.1bn |
| jpcrp040300-q2r_E02344-000Japan Semiconductor Relatedreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥620m |
| jpcrp040300-q2r_E02344-000Measuring Instrumentsreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥14.6bn |
| jpcrp040300-q2r_E02344-000Measuring Instrumentsreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥11.6bn |
| jpcrp040300-q2r_E02344-000Measuring Instrumentsreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥3.0bn |
| jpcrp040300-q2r_E02344-000Measuring Instrumentsreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥460m |
| jpcrp040300-q2r_E02344-000Medical And Health Systemreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥18.5bn |
| jpcrp040300-q2r_E02344-000Medical And Health Systemreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥10.1bn |
| jpcrp040300-q2r_E02344-000Medical And Health Systemreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥8.4bn |
| jpcrp040300-q2r_E02344-000Medical And Health Systemreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥2.0bn |
| jpcrp040300-q2r_E02344-000Semiconductor Related Businessreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥2.1bn |
| jpcrp040300-q2r_E02344-000Semiconductor Related Businessreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥2.1bn |
| jpcrp040300-q2r_E02344-000Semiconductor Related Businessreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥620m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 620
| Item | Context | Value | Unit |
|---|---|---|---|
| Comprehensive income | Prior1YTDDuration | 1653000000 | JPY |
| Comprehensive income | CurrentYTDDuration | 5313000000 | JPY |
| Comprehensive income attributable to owners of the parent | Prior1YTDDuration | 1498000000 | JPY |
| Comprehensive income attributable to owners of the parent | CurrentYTDDuration | 5301000000 | JPY |
| Comprehensive income attributable to non controlling interests | Prior1YTDDuration | 155000000 | JPY |
| Comprehensive income attributable to non controlling interests | CurrentYTDDuration | 11000000 | JPY |
| Income before income taxes | Prior1YTDDuration | 2170000000 | JPY |
| Income before income taxes | CurrentYTDDuration | 2227000000 | JPY |
| Depreciation and amortization ope cf | Prior1YTDDuration | 780000000 | JPY |
| Depreciation and amortization ope cf | CurrentYTDDuration | 821000000 | JPY |
| Amortization of goodwill ope cf | Prior1YTDDuration | 45000000 | JPY |
| Amortization of goodwill ope cf | CurrentYTDDuration | 46000000 | JPY |
| Depreciation of trademark | Prior1YTDDuration | 25000000 | JPY |
| Depreciation of trademark | CurrentYTDDuration | 0 | JPY |
| Increase decrease in allowance for doubtful accounts ope cf | Prior1YTDDuration | -22000000 | JPY |
| Increase decrease in allowance for doubtful accounts ope cf | CurrentYTDDuration | -35000000 | JPY |
| Interest and dividends income ope cf | Prior1YTDDuration | -32000000 | JPY |
| Interest and dividends income ope cf | CurrentYTDDuration | -96000000 | JPY |
| Interest expenses ope cf | Prior1YTDDuration | 69000000 | JPY |
| Interest expenses ope cf | CurrentYTDDuration | 106000000 | JPY |
| Subsidy income ope cf | Prior1YTDDuration | -116000000 | JPY |
| Subsidy income ope cf | CurrentYTDDuration | － | JPY |
| Settlement package ope cf | Prior1YTDDuration | 44000000 | JPY |
| Settlement package ope cf | CurrentYTDDuration | － | JPY |
| Theft loss ope cf | Prior1YTDDuration | 65000000 | JPY |
| Theft loss ope cf | CurrentYTDDuration | － | JPY |
| Decrease increase in notes and accounts receivable trade ope cf | Prior1YTDDuration | 946000000 | JPY |
| Decrease increase in notes and accounts receivable trade ope cf | CurrentYTDDuration | 1462000000 | JPY |
| Decrease increase in inventories ope cf | Prior1YTDDuration | -2009000000 | JPY |
| Decrease increase in inventories ope cf | CurrentYTDDuration | -2358000000 | JPY |
| Increase decrease in notes and accounts payable trade ope cf | Prior1YTDDuration | 835000000 | JPY |
| Increase decrease in notes and accounts payable trade ope cf | CurrentYTDDuration | 60000000 | JPY |
| Increase decrease in provision for bonuses ope cf | Prior1YTDDuration | 13000000 | JPY |
| Increase decrease in provision for bonuses ope cf | CurrentYTDDuration | 50000000 | JPY |
| Increase decrease in provision for product warranties ope cf | Prior1YTDDuration | 15000000 | JPY |
| Increase decrease in provision for product warranties ope cf | CurrentYTDDuration | 9000000 | JPY |
| Increase decrease in net defined benefit asset ope cf | Prior1YTDDuration | -23000000 | JPY |
| Increase decrease in net defined benefit asset ope cf | CurrentYTDDuration | -20000000 | JPY |
| Increase decrease in net defined benefit liability ope cf | Prior1YTDDuration | -58000000 | JPY |
| Increase decrease in net defined benefit liability ope cf | CurrentYTDDuration | -69000000 | JPY |
| Other net ope cf | Prior1YTDDuration | 257000000 | JPY |
| Other net ope cf | CurrentYTDDuration | 0 | JPY |
| Subtotal ope cf | Prior1YTDDuration | 3004000000 | JPY |
| Subtotal ope cf | CurrentYTDDuration | 2204000000 | JPY |
| Interest and dividends income received ope cf inv cf | Prior1YTDDuration | 32000000 | JPY |
| Interest and dividends income received ope cf inv cf | CurrentYTDDuration | 96000000 | JPY |
| Interest expenses paid ope cf fin cf | Prior1YTDDuration | -70000000 | JPY |
| Interest expenses paid ope cf fin cf | CurrentYTDDuration | -102000000 | JPY |
| Settlement package paid ope cf | Prior1YTDDuration | -44000000 | JPY |
| Settlement package paid ope cf | CurrentYTDDuration | － | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |